Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same author

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Investigational new drugs·2026
Same author

Management of peripheral-vein leiomyosarcomas, recurrence patterns and individualised treatment strategy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

A novel risk score after neoadjuvant imatinib predicts relapse-free survival in patients with gastrointestinal stromal tumours (GIST).

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Efficacy and cardiac safety of aldoxorubicin in metastatic solitary fibrous tumour.

Rare tumors·2025
Same author

Comparison of MRI imaging features to differentiate degenerating fibroids from uterine leiomyosarcomas.

Rare tumors·2025

Related Experiment Video

Updated: May 4, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K

Current management options for liposarcoma and challenges for the future.

Attila Kollár1, Charlotte Benson

  • 1The Royal Marsden Hospital, Sarcoma Unit, Fulham Road, SW3 6JJ, London, UK.

Expert Review of Anticancer Therapy
|January 9, 2014
PubMed
Summary
This summary is machine-generated.

Liposarcoma (LS) is a common soft tissue sarcoma, often resistant to chemotherapy except for the myxoid subtype. Current treatments include conventional agents and targeted therapies, with ongoing research into novel strategies for better outcomes.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

13.7K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K

Related Experiment Videos

Last Updated: May 4, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

13.7K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Pharmacology

Background:

  • Liposarcoma (LS) is a prevalent soft tissue sarcoma with distinct subtypes: well/dedifferentiated, myxoid/round cell, and pleomorphic.
  • LS generally exhibits chemoresistance, with the myxoid variant being a notable exception.
  • Current first-line systemic treatment relies on conventional chemotherapy, including doxorubicin and ifosfamide.

Purpose of the Study:

  • To review current systemic treatment options for liposarcoma.
  • To discuss novel therapeutic strategies and emerging molecular targets.
  • To provide an overview of the evolving landscape of liposarcoma management.

Main Methods:

  • Literature review of current systemic treatment options for liposarcoma.
  • Analysis of recent advancements in molecular diagnostics for LS subtypes.
  • Examination of novel therapeutic targets and early-phase clinical trial data.

Main Results:

  • Conventional chemotherapy (doxorubicin, ifosfamide) remains a primary treatment modality.
  • Active cytotoxic agents include gemcitabine, docetaxel, and trabectedin.
  • Emerging molecular targets, such as MDM2 and CDK4 amplification, are identified for specific LS subtypes, though clinical application is pending further trials.

Conclusions:

  • Despite progress in molecular understanding, new drugs have yet to be integrated into routine clinical practice.
  • The review highlights the need for continued research into novel systemic therapies for liposarcoma.
  • Targeted therapies based on molecular diagnostics represent a promising future direction for liposarcoma treatment.